ERBB2 and breast cancer: To identify genes whose suppression converts the cytostatic response to PI3K inhibition into a cytotoxic response, we performed a positive-selection genome scale shRNA screen (Figure 1A) using MDA-MB-453 breast cancer cells, which harbor a PIK3CA H1047R mutation and ERBB2 amplification.